MX2023002478A - Profarmacos de abiraterona. - Google Patents

Profarmacos de abiraterona.

Info

Publication number
MX2023002478A
MX2023002478A MX2023002478A MX2023002478A MX2023002478A MX 2023002478 A MX2023002478 A MX 2023002478A MX 2023002478 A MX2023002478 A MX 2023002478A MX 2023002478 A MX2023002478 A MX 2023002478A MX 2023002478 A MX2023002478 A MX 2023002478A
Authority
MX
Mexico
Prior art keywords
abiraterone
prodrugs
syndrome due
excess
hypercortisolemia
Prior art date
Application number
MX2023002478A
Other languages
English (en)
Spanish (es)
Inventor
Matthew J Sharp
William R Moore Jr
Original Assignee
Propella Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Propella Therapeutics Inc filed Critical Propella Therapeutics Inc
Publication of MX2023002478A publication Critical patent/MX2023002478A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28Antiandrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2023002478A 2020-09-02 2021-09-01 Profarmacos de abiraterona. MX2023002478A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063073502P 2020-09-02 2020-09-02
PCT/US2021/048607 WO2022051330A1 (en) 2020-09-02 2021-09-01 Abiraterone prodrugs

Publications (1)

Publication Number Publication Date
MX2023002478A true MX2023002478A (es) 2023-03-27

Family

ID=77951832

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002478A MX2023002478A (es) 2020-09-02 2021-09-01 Profarmacos de abiraterona.

Country Status (9)

Country Link
US (1) US20240050447A1 (enExample)
EP (1) EP4208171A1 (enExample)
JP (1) JP7850366B2 (enExample)
CN (1) CN116490165A (enExample)
AU (1) AU2021338271A1 (enExample)
CA (1) CA3189989A1 (enExample)
IL (1) IL300837A (enExample)
MX (1) MX2023002478A (enExample)
WO (1) WO2022051330A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7644713B2 (ja) 2019-03-06 2025-03-12 プロペラ セラピューティクス インコーポレイテッド アビラテロンプロドラッグ
CA3207282A1 (en) * 2021-02-15 2022-08-18 Matthew J. Sharp Abiraterone prodrugs
WO2024107928A1 (en) 2022-11-16 2024-05-23 Propella Therapeutics, Inc. Abiraterone decanoate composition and use in therapy
CN116287275B (zh) * 2023-04-10 2024-04-05 广州市第一人民医院(广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院) Ptgr1作为cdk4/6抑制剂与二甲双胍联合用药指导标志物的应用
WO2025240673A1 (en) * 2024-05-15 2025-11-20 Cardiff Oncology, Inc. Cancer treatment using akt inhibitors and plk1 inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20121788A1 (it) * 2012-10-22 2014-04-23 Olon Spa Procedimento per la purificazione di abiraterone acetato
US20150337003A1 (en) * 2013-01-18 2015-11-26 Cortendo Ab (Publ) Abiraterone and analogs thereof for the treatment of diseases associated with cortisol overproduction
CN104017045B (zh) * 2014-06-23 2016-01-13 广州艾格生物科技有限公司 甾体cyp17抑制剂的新型药物前体及其应用、制备方法
US10722527B2 (en) * 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
CA3008909C (en) * 2015-12-23 2023-10-03 The University Of British Columbia Lipid-linked prodrugs
CN106977577A (zh) * 2017-04-21 2017-07-25 湖南师范大学 两类阿比特龙衍生物的合成
CN118684633A (zh) 2018-10-18 2024-09-24 埃萨制药股份有限公司 雄激素受体调节剂及其使用方法
JP7644713B2 (ja) * 2019-03-06 2025-03-12 プロペラ セラピューティクス インコーポレイテッド アビラテロンプロドラッグ
CA3207282A1 (en) * 2021-02-15 2022-08-18 Matthew J. Sharp Abiraterone prodrugs
CN118215466A (zh) * 2021-09-08 2024-06-18 普洛佩拉治疗公司 口服阿比特龙制剂
KR20240167653A (ko) * 2022-03-01 2024-11-27 프로펠라 쎄라퓨틱스, 인크. 아비라테론 데카노에이트 프로드러그 및 요법에서의 용도

Also Published As

Publication number Publication date
IL300837A (en) 2023-04-01
JP2023539371A (ja) 2023-09-13
CA3189989A1 (en) 2022-03-10
AU2021338271A1 (en) 2023-03-30
EP4208171A1 (en) 2023-07-12
CN116490165A (zh) 2023-07-25
JP7850366B2 (ja) 2026-04-23
US20240050447A1 (en) 2024-02-15
WO2022051330A1 (en) 2022-03-10

Similar Documents

Publication Publication Date Title
BR112021017377A2 (pt) Pró-fármacos de abiraterona
JOP20190244A1 (ar) تركيبة علاجية لسرطان البروستاتا
PH12020551195A1 (en) Methods and compositions for macrophage polarization
CY1125112T1 (el) Προφαρμακα ριλουζολης και χρηση αυτων
MX2019012038A (es) Composiciones que comprenden una combinacion de un anticuerpo anti gen 3 de activacion del linfocito (lag-3), un inhibidor de la trayectoria del receptor de muerte programada 1 (pd-1), y un agente inmunoterapeutico.
AU2016256469A8 (en) Methods for treating cancer
PH12018502048A1 (en) Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
MX2019008158A (es) Terapia de combinacion para el tratamiento del cancer.
MX2018011419A (es) Moduladores de receptores estrogénicos.
CR20170216A (es) Composiciones anticancerígenas
WO2019143883A3 (en) Compositions and methods for the treatment of cancer
MX2022008099A (es) Tratamiento para el cancer con inhibidores de cdk12/13.
WO2020055643A3 (en) Compounds, compositions and methods for treating or preventing her-driven cancers
WO2022031642A3 (en) Uses of glucocorticoid receptor (gr) antagonist and androgen receptor (ar) degrader combinations
MX2022000853A (es) Anticuerpos anti-liv1 humanizados para el tratamiento de cancer.
CU24027B1 (es) Derivados de piridazina como inhibidores de smo
MX2024003797A (es) Conjugados de anticuerpos b7-h4 y farmacos para el tratamiento del cancer.
PH12020550151A1 (en) Methods of treating prostate cancer
MX2020003388A (es) Composiciones y metodos para tratar cancer hepatico.
MX2024010741A (es) Profarmacos de decanoato de abiraterona y uso en terapia.
MX2022005139A (es) Sales y formas de un modulador de receptores estrogénicos.
IL304400A (en) Compounds and methods for preventing tumors and cancer
MX2025004219A (es) Compuestos, composiciones y metodos
WO2019241644A8 (en) Novel small molecule anticancer agents, combinations and uses thereof
MX2023003404A (es) Anticuerpos anti-l1vi humanizados para el tratamiento del cancer.